JAMA Neurology Publishes Results from Positive Phase 3 Trial of EPIDIOLEX® (cannabidiol) oral solution in Children with Seizures Associated with Dravet SyndromeGlobeNewsWire • 03/02/20
GW Pharmaceuticals regains exclusive commercialisation rights to Sativex® (nabiximols) in the UK from BayerGlobeNewsWire • 03/02/20
Why A CBD-Oil Seizure Drug Will Make — Or Break — This Biotech StockInvestors Business Daily • 02/26/20
GW Pharmaceuticals plc (GWPH) CEO Justin Gover on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/26/20
GW Pharmaceuticals PLC (GWPH) Gains As Market Dips: What You Should KnowZacks Investment Research • 02/20/20
GW Pharmaceuticals PLC (GWPH) Outpaces Stock Market Gains: What You Should KnowZacks Investment Research • 02/11/20
GW Pharmaceuticals PLC (GWPH) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 02/03/20
GW Pharmaceuticals and Greenwich Biosciences Submit Supplemental New Drug Application to U.S. FDA for Epidiolex® (cannabidiol) for the Treatment of Tuberous Sclerosis ComplexGlobeNewsWire • 02/03/20